Sarah Kremen, MD
Neurology · Los Angeles, CANPI 1144348848
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,825 of the $5,712 with a category attached, or 67.0%. Eli Lilly accounts for 69.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $2,250 and has fallen 98.3% since, to $38 in 2025.
Across 25 payments — averaging $228.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$4K
- Eisai Inc.$1K
- Genentech, Inc.$152
- Biogen$63
- Life Molecular Imaging Ltd$38
Across 64 payments — averaging $20,048 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$676K
- Eli Lilly$521K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$33K
- Novo Nordisk AS$30K
- Genentech, Inc.$21K
- Biogen$2K
- plus $62 from 1 others
What the payments were for
- Consulting fees$3,82567%
- Travel & lodging$1,10219%
- Food & beverage$63311%
- Education$1523%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 4 | $3,976 |
| Eisai Inc. | 14 | $1,482 |
| Genentech, Inc. | 4 | $152 |
| Biogen | 1 | $63 |
| Life Molecular Imaging Ltd | 2 | $38 |
How this compares
$5,712 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 15 | $2,001 |
| Memantine Hcl ErMemantine Hcl | 12 | $1,509 |
| Memantine Hcl | 30 | $590 |
| Donepezil Hcl | 43 | $410 |
| Sertraline Hcl | 26 | $180 |
Paid to pharmacies, not to this prescriber.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.